+

US20060183176A1 - Method and reagent for detecting cell death - Google Patents

Method and reagent for detecting cell death Download PDF

Info

Publication number
US20060183176A1
US20060183176A1 US11/402,538 US40253806A US2006183176A1 US 20060183176 A1 US20060183176 A1 US 20060183176A1 US 40253806 A US40253806 A US 40253806A US 2006183176 A1 US2006183176 A1 US 2006183176A1
Authority
US
United States
Prior art keywords
cytochrome
reagent
cell death
encephalopathy
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/402,538
Inventor
Fumio Endo
Naoto Adachi
Hiroyuki Nunoi
Keisuke Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to US11/402,538 priority Critical patent/US20060183176A1/en
Assigned to EISAI CO., LTD. reassignment EISAI CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WATANABE, KEISUKE, NUNOI, HIROYUKI, ADACHI, NAOTO, ENDO, FUMIO
Publication of US20060183176A1 publication Critical patent/US20060183176A1/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EISAI CO., LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Definitions

  • the present invention relates to a method and a reagent for detecting cell death.
  • GVHD graft versus host disease
  • HPS hemophagocytic syndrome
  • VAHS virus associated hemophagocytic syndrome
  • GVHD and HPS may be diagnosed by detecting apoptosis.
  • chromatin codensation method in which DNA fragmentation specifically occurring during apoptosis is detected by staining, and a method of detecting morphologic change specific to apoptosis by observation under an electron microscope or measurement of a cell size.
  • a method of ligating a labeled nucleotide to a terminus of a DNA fragment and detecting it by a fluorescence microscope As another method, a flow cytometry is also used, in which amounts of intracellular substances are measured for individual cells.
  • a solid phase enzyme immunoassay (enzyme-linked immunosorbent assay, ELISA) for detecting histone-binding DNA fragments (mono- or oligo-nucleosome) has been developed (Cell Detection ELISA: Boehringer Mannheim, Kokusan Chemical).
  • An object of the present invention is to develop a method and a reagent for detecting apoptosis occurring in a living body, which are simple and show superior sensitivity and quantitation performance.
  • Cytochrome C is known as an important protein in the electron transport system in mitochondria. It is reported that, when a cell is exposed to a stimulus that triggers apoptosis and enters into an apoptosis state, cytochrome C in the mitochondria is rapidly released into cytosol (Dinsdale, D. et al., American J. Pathol. 155: 607-18, 1999). It is also reported that cytochrome C in the cytosol is associated with activation of caspase-3, which is a key factor of apoptosis, and an increase of cytochrome C is involved in the progress of apoptosis (Medina, V. et al., Cancer Research, 57: 3697-707, 1999).
  • the inventors of the present invention considered that, when apoptosis occurred in a living body, cytochrome C released from mitochondria could also be measured in blood. Then, they established an ELISA method for measuring cytochrome C, and found that the cytochrome C level in blood strongly correlated with progress of GVHD, HPS, acute lymphatic leukemia and influenzal encephalopathy. Thus, they accomplished the present invention.
  • the present invention provides a method for detecting cell death occurring in a living body by determining cytochrome C in body fluid, and a method and a reagent for measuring cytochrome C that can be used in such a method, which are described below.
  • a method for detecting cell death which comprises determining cytochrome C in body fluid and detecting cell death based on a determined value.
  • a method for measuring cytochrome C which comprises determining cytochrome C in body fluid by a sandwich method.
  • a reagent for measuring cytochrome C for determination of cytochrome C in body fluid by a sandwich method which comprises an antibody directed to cytochrome C as an ingredient.
  • FIG. 1 shows changes in values of LDH, AST, ALT, ferritin and cytochrome C (Cyto-C) in sera of HPS patients.
  • FIG. 2 shows cytochrome C levels in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy.
  • FIG. 3 shows changes in values of GOT, LDH and cytochrome C in blood of patients having developed influenzal encephalopathy.
  • FIG. 4 shows levels of various cytokines in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy.
  • cytochrome C transferred from mitochondria to cytoplasm in response to an apoptosis signal is released outside a cell due to destruction of a cell membrane as a result of cell death.
  • the present invention is based on findings that cytochrome C released outside a cell due to cell death can be detected by determining cytochrome C in body fluid such as blood, and that cell death occurring in a living body can be detected by determining cytochrome-C in body fluid. Therefore, any methods for detecting cell death by determining cytochrome C in body fluid fall within the scope of the present invention.
  • cell death used herein primarily refers to apoptosis. However, it is not easy to identify cell death generally occurring in a living body as apoptosis, and any cell death accompanied by an increase of cytochrome C in body fluid is included in the cell death referred to in the present invention.
  • body fluid refers to blood, plasma, serum, cerebrospinal fluid or the like collected from a living body.
  • an immunochemical method As the method for measuring cytochrome C, there can be mentioned an immunochemical method, method utilizing electrophoresis, method utilizing chromatography and so forth.
  • the methods utilizing electrophoresis include a method wherein polyacrylamide gel electrophoresis is performed to detect cytochrome C as a band, a method wherein capillary electrophoresis is performed to detect cytochrome C as a peak and so forth.
  • the method utilizing chromatography a method wherein high performance liquid chromatography is performed to detect cytochrome C as a peak and so forth can be mentioned.
  • fluorescence labeling may be used in some cases, but the present invention is not limited to such cases.
  • an immunochemical method As the method for measuring cytochrome C, an immunochemical method is preferred in view of sensitivity and simplicity.
  • the term “immunochemical method” used herein refers to a method of determining cytochrome C by using an antibody directed to cytochrome C.
  • the immunochemical method there can be mentioned various methods such as a competitive method in which cytochrome C is labeled,. a sandwich method in which an antibody is labeled, a latex bead method in which agglutination of antibody-coated beads is observed and so forth, and they are included in preferred embodiments of the present invention so long as an antibody directed to cytochrome C is used.
  • the antibody may be a monoclonal or polyclonal antibody.
  • labeling method there can also be mentioned various methods such as labeling with a radioactive isotope, labeling with a compound showing electro-chemiluminescence, fluorescence labeling, labeling with an enzyme, labeling with biotin and so forth, but the present invention is not limited to these examples.
  • An antibody directed to cytochrome C is immobilized on beads or a cup.
  • the beads may be microbeads. In this case, microbeads of magnetic substance are preferred.
  • the immobilization may be achieved by a covalent or non-covalent bond. Usually, nonspecific binding sites on the beads or cup are blocked by using a protein such as bovine serum albumin (BSA) or casein or a surfactant such as Tween 20.
  • BSA bovine serum albumin
  • Tween 20 a surfactant
  • a specimen is diluted with a buffer containing a protein such as BSA or casein or a surfactant such as Tween 20, if required, and added to the beads or the cup. Further, a known amount of cytochrome C is similarly diluted and added.
  • the beads or the cup are/is washed with a buffer-containing a surfactant such as Tween 20, if required, and a labeled antibody diluted with a buffer containing a protein such as BSA or casein or a surfactant such as Tween 20, if required, is added thereto.
  • a buffer-containing a surfactant such as Tween 20, if required
  • the beads or the cup are/is washed with a buffer containing a surfactant such as Tween 20, if required, and measurement is performed by a method corresponding with the label. For example, radioactivity is measured when it is radioactively labeled, or enzymatic activity is measured when it is labeled with an enzyme. Further, when it is labeled with biotin, labeled avidin is further added and measurement is performed by a method corresponding with the label.
  • a surfactant such as Tween 20
  • a calibration curve is created by using known amounts of cytochrome C, and the amount of cytochrome C contained in the specimen is calculated.
  • cytochrome C in the specimen is determined.
  • cytochrome C When the determined value of cytochrome C is higher than a normal value, it can be considered that cell death is detected.
  • the present invention also relates to a method for measuring cytochrome C, which comprises determining cytochrome C in body fluid by a sandwich method.
  • the sandwich method is an immunochemical method such as ELISA utilizing an antigen sandwiched by an immobilized antibody and a labeled antibody.
  • cytochrome C As the method for measuring cytochrome C by an immunochemical method, a dot blot method is widely used (Souichi A. et al., J. Biological Chem. 273: 19892-4, 1998). However, while this method can measure cytochrome C in a cell homogenate containing a high content of cytochrome C and a low concentration of protein, this is not suitable for determining cytochrome C with high sensitivity in body fluid containing a low content of cytochrome C and a high concentration of protein.
  • the present invention is based on a finding that even such a trace amount of cytochrome C in body fluid as released due to cell death occurring in a living body can be detected by using ELISA based on the sandwich method to determine cytochrome C in the body fluid containing a high concentration of protein with high sensitivity.
  • the present invention also relates to a reagent for measuring cytochrome C, which comprises an antibody directed to cytochrome C as an ingredient and used for determining cytochrome C in body fluid by the sandwich method.
  • This measurement reagent may have the same constitution as that of a reagent (kit) used in a usual sandwich method except that the anti-cytochrome C antibody is used as an antibody.
  • the reagent for measuring cytochrome C by the sandwich method may contain 1) an anti-cytochrome C antibody-coated solid phase such as an anti-cytochrome C antibody-coated cup or anti-cytochrome C antibody-coated beads, 2) a labeled anti-cytochrome C antibody, 3) a cytochrome C standard solution of a known concentration, 4) a diluent and 5) a washing solution. Further, if labeling with an enzyme is used, 6) a chromogenic substrate and 7) a solution for terminating a reaction may be included.
  • an anti-cytochrome C antibody-coated solid phase such as an anti-cytochrome C antibody-coated cup or anti-cytochrome C antibody-coated beads
  • a labeled anti-cytochrome C antibody such as an anti-cytochrome C antibody-coated cup or anti-cytochrome C antibody-coated beads
  • a labeled anti-cytochrome C antibody such as an anti-cytochrome C antibody-coated cup or anti
  • the method and the reagent for measuring cytochrome C disclosed by the present invention enable detection of cell death. Therefore, it becomes possible to provide a diagnostic indicator for diagnosis of various diseases accompanied with apoptosis such as differential diagnosis or follow-up of the diseases.
  • a method and reagent for measuring cytochrome C for the purpose of detection of cell death or diagnosis of a disease accompanied with apoptosis are provided.
  • VAHS virus associated hemophagocytic syndrome
  • HCV virus associated hemophagocytic syndrome
  • Leukemia for example, acute lymphatic leukemia
  • SIRS Systemic inflammatory reaction syndrome
  • encephalitis and encephalopathy are diseases induced by viral infection.
  • encephalitis and encephalopathy caused by influenza virus account for a large proportion of causes of death by influenza, but it is difficult to differentiate the diseases from heat cramp, and a method of accurate early diagnosis for providing appropriate treatment therefor is required.
  • the measurement method and the measurement reagent of the present invention enable accurate and early diagnosis.
  • cytochrome C By measuring cytochrome C in body fluid, cell death progressing in a living body can be determined, and hence progress of these diseases can be monitored.
  • HPS hemophagocytic syndrome
  • VAHS virus associated hemophagocytic syndrome
  • determination of cytochrome C is useful to understand the conditions of the diseases.
  • Cytochrome C in body fluid is a favorable indicator of cell death occurring in a living body, and can be a useful indicator to find a pathological condition early and accurately.
  • % refers to % by mass unless otherwise indicated.
  • Cytochrome C is measured by the following procedure.
  • a rabbit is immunized with rat cytochrome C (Sigma) to obtain antiserum directed to cytochrome C.
  • ammonium sulfate is added at a final concentration of 2 M, and it is stirred at room temperature (20-30° C.) for 5 hours.
  • the stirred solution is centrifuged at 10000 rpm for 30 minutes and the supernatant is discarded.
  • the precipitation is dissolved in 0.1 M phosphate buffer (pH 7.2) and dialyzed against the same buffer.
  • the dialyzed solution is applied to a column of a carrier obtained by binding bovine cytochrome C to CNBr-Sepharose 4B (Pharmacia).
  • the column is washed with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl, and then anti-cytochrome C antibodies are eluted with 0.1 M guanidine hydrochloride.
  • the eluted solution is dialyzed against 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl to obtain purified antibodies (IgG).
  • the purified IgG is dialyzed against 0.1 M acetate buffer (pH 4.2).
  • pepsin Sigma
  • pepsin Sigma
  • the solution after the reaction is adjusted to pH 7.5 with 1 N NaOH and subjected to gel filtration by using a Sephacryl S-200 (Pharmacia) column equilibrated with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl.
  • a first peak of the fractions obtained from the gel filtration is collected and concentrated to obtain an anti-cytochrome C antibody F(ab′) 2 solution.
  • the purified IgG obtained in 1) is adjusted to an absorbance of 0.1 with 0.01 M Tris-HCl buffer (pH 7.5).
  • 100 ⁇ l of this antibody solution is introduced into a polystyrene cup, and allowed to react at 4° C. for 16 hours and the cup is washed three times (for 4 seconds each time) with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl and 0.01% Tween 20 by using a washer designed for use in EIA.
  • 200 ⁇ l of 0.01 M Tris-HCl buffer (pH 7.5) containing 0.5% bovine albumin is added to the washed cup and allowed to react at 4° C. for 16 hours again to obtain an antibody-immobilized solid phase cup.
  • Rat cytochrome C (Sigma) is diluted with 0.05 M Tris buffer (pH 7.5) containing 2% BSA, 0.01 M EDTA 2Na, 0.1% NaN 3 , 0.01% Tween 20 and 0.15 M NaCl to prepare 50-0.05 ng/ml dilutions.
  • the bovine albumin solution in the anti-cytochrome C antibody-immobilized cup is sucked out and 50 ⁇ l of 0.05 M Tris buffer (pH 7.5) containing 2% BSA, 0.01 M EDTA 2Na, 0.1% NaN 3 , 0.01% Tween 20 and 0.15 M NaCl is introduced into the aforementioned cup.
  • 50 ⁇ l each of diluted standard antigen solutions and a specimen is added to the cup and allowed to react at room temperature (20-30° C.) for 1 hour. After the reaction, the cup is washed three times (for 4 seconds each time) with 0.005 M Tris buffer (pH.
  • Absorbance value of a blank is subtracted from each of absorbance values of the cytochrome C at various concentrations and the specimen.
  • the standard antigen concentration and the absorbance of the standard antigen are plotted on the horizontal axis and the vertical axis, respectively, to draw a standard curve. Based on the standard antigen curve, the amount of cytochrome C contained in the specimen is calculated.
  • Cytochrome C levels in sera of GVHD, HPS and acute lymphatic leukemia patients and normal subjects were measured by using the ELISA system for measuring cytochrome C described in Example 1.
  • cytochrome C changes in values of LDH, AST, ALT, ferritin and cytochrome C in sera of HPS patients are shown in FIG. 1 .
  • the cytochrome C value substantially correlated with the LDH and its change preceded that of LDH. Therefore, cytochrome C is considered to be useful as an indicator for sensitively reflecting changes in pathological conditions.
  • the amounts of cytochrome C in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy were measured by using the ELISA system described in Example 1.
  • results including those of multiple measurements for one patient are shown in FIG. 2 .
  • all 27 specimens (8 cases) showed high values not lower than 5 ng/ml, and among these, 17 specimens showed high values not lower than 30 ng/ml.
  • patients having a high blood cytochrome C concentration tended to show poor course of the disease.
  • FIG. 3 changes in values of GOT, LDH and cytochrome C in blood of influenzal encephalopathy patients are shown in FIG. 3 .
  • E-selectin Concentrations of E-selectin, soluble thrombomodulin (sTM), tumor necrosis factor (TNF), Fas, FasL and cytochrome. C in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy were determined.
  • E-selectin was measured by using sE-Selectin ELISA Kit (Version 2, Bender Med Systems).
  • sTM was measured by using TM Test (Teijin Diagnostics).
  • TNF was measured by using Human TNF- ⁇ Cytoscreen Immunoassay Kit (Biosource International).
  • Fas was measured by using sFas ELISA Kit, and FasL was measured by using sFas Ligand ELISA Kit (both produced by Medical and Biological Laboratories). Cytochrome C was measured by using the ELISA system described in Example 1.
  • cytochrome C As shown in FIG. 4 , for all of the cytokines, number of cases showing high determined values increased for sera of encephalitis or encephalopathy patients. However, cytochrome C most markedly increased in encephalitis or encephalopathy patients. Thus, it was revealed that cytochrome C was the most suitable for differential diagnosis of encephalitis or encephalopathy.
  • the present invention provides an immunochemical method suitable for determination of cytochrome C in body fluid. Further, it was revealed that cytochrome C was a favorable indicator of cell death occurring in a living body and a useful indicator to find a pathological condition early and accurately. Therefore, measurement of cytochrome C is useful for diagnosis such as differential diagnosis or follow-up of diseases in which apoptosis is involved in progress of their pathological conditions, in particular, GVHD, HPS, acute lymphatic leukemia and influenzal encephalitis or encephalopathy.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for detecting cell death, which comprises determining cytochrome C in body fluid and detecting cell death based on a quantified value, as well as a method for determining cytochrome C in body fluid by a sandwich method and a reagent for measuring cytochrome C for determination cytochrome C in body fluid by a sandwich method, which comprises an antibody directed to cytochrome C as an ingredient.

Description

    TECHNICAL FIELD
  • The present invention relates to a method and a reagent for detecting cell death.
    • BACKGROUND ART
  • Graft versus host disease (GVHD), which is a disease that is caused after bone marrow transplantation and damages many organs; hemophagocytic syndrome (HPS), which is a disease where blood cells are phagocytized by phagocytes, especially virus associated hemophagocytic syndrome (VAHS) occurring after viral infection; and so forth are severe diseases that cause organ failures and eventually lead to death. Currently, cytologic diagnosis such as biopsy is generally used for diagnosing these diseases. However, such diagnosis suffers from drawbacks in view of patient's pain during the test, time required for diagnosis and operation procedures.
  • Since it has been found in recent years that a major cause of GVHD and HPS is cell apoptosis in living bodies, it is considered that GVHD and HPS may be diagnosed by detecting apoptosis.
  • As methods for detecting apoptosis, there have conventionally been used 1) morphologic methods, 2) histochemical methods, 3) biochemical methods and 4) immunochemical methods.
  • 1) Morphologic methods
  • There are used the chromatin codensation method, in which DNA fragmentation specifically occurring during apoptosis is detected by staining, and a method of detecting morphologic change specific to apoptosis by observation under an electron microscope or measurement of a cell size.
  • 2) Histochemical methods
  • There is used a method of ligating a labeled nucleotide to a terminus of a DNA fragment and detecting it by a fluorescence microscope. As another method, a flow cytometry is also used, in which amounts of intracellular substances are measured for individual cells.
  • 3) Biochemical methods
  • There is used a method of detecting a DNA ladder by agarose gel electrophoresis. This is currently considered to be the most reliable method for identifying apoptosis. However, since DNA is extracted from a tissue or a cell population as a whole, it is said that this method has a problem in sensitivity and quantitation performance when the proportion of apoptotic cells is not high.
  • 4) Immunochemical methods
  • A solid phase enzyme immunoassay (enzyme-linked immunosorbent assay, ELISA) for detecting histone-binding DNA fragments (mono- or oligo-nucleosome) has been developed (Cell Detection ELISA: Boehringer Mannheim, Kokusan Chemical).
  • However, these methods have problems such as complicated procedures and poor sensitivity and quantification performance, and have not been currently used in practice as methods for diagnosing GVHD and HPS.
    • DISCLOSURE OF THE INVENTION
  • An object of the present invention is to develop a method and a reagent for detecting apoptosis occurring in a living body, which are simple and show superior sensitivity and quantitation performance.
  • Cytochrome C is known as an important protein in the electron transport system in mitochondria. It is reported that, when a cell is exposed to a stimulus that triggers apoptosis and enters into an apoptosis state, cytochrome C in the mitochondria is rapidly released into cytosol (Dinsdale, D. et al., American J. Pathol. 155: 607-18, 1999). It is also reported that cytochrome C in the cytosol is associated with activation of caspase-3, which is a key factor of apoptosis, and an increase of cytochrome C is involved in the progress of apoptosis (Medina, V. et al., Cancer Research, 57: 3697-707, 1999).
  • The inventors of the present invention considered that, when apoptosis occurred in a living body, cytochrome C released from mitochondria could also be measured in blood. Then, they established an ELISA method for measuring cytochrome C, and found that the cytochrome C level in blood strongly correlated with progress of GVHD, HPS, acute lymphatic leukemia and influenzal encephalopathy. Thus, they accomplished the present invention.
  • The present invention provides a method for detecting cell death occurring in a living body by determining cytochrome C in body fluid, and a method and a reagent for measuring cytochrome C that can be used in such a method, which are described below.
  • (1) A method for detecting cell death, which comprises determining cytochrome C in body fluid and detecting cell death based on a determined value.
  • (2) The method for detecting cell death according to (1), wherein cytochrome C is determined by an immunochemical method.
  • (3) A method for measuring cytochrome C, which comprises determining cytochrome C in body fluid by a sandwich method.
  • (4) A reagent for measuring cytochrome C for determination of cytochrome C in body fluid by a sandwich method, which comprises an antibody directed to cytochrome C as an ingredient.
  • (5) The reagent for measuring cytochrome C according to (4), which is used for detection of cell death.
  • (6) The reagent for measuring cytochrome C according to (4), which is used for diagnosis of graft versus host disease (GVHD).
  • (7) The reagent for measuring cytochrome C according to (4), which is used for diagnosis of hemophagocytic syndrome (HPS).
  • (8) The reagent for measuring cytochrome C according to (4), which is used for diagnosis of acute lymphatic leukemia.
  • (9) The reagent for measuring cytochrome C according to (4), which is used for diagnosis of viral encephalitis or encephalopathy.
  • (10) The reagent for measuring cytochrome C according to (9), wherein the viral encephalitis or encephalopathy is influenzal encephalitis or encephalopathy.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows changes in values of LDH, AST, ALT, ferritin and cytochrome C (Cyto-C) in sera of HPS patients.
  • FIG. 2 shows cytochrome C levels in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy.
  • FIG. 3 shows changes in values of GOT, LDH and cytochrome C in blood of patients having developed influenzal encephalopathy.
  • FIG. 4 shows levels of various cytokines in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Hereafter, embodiments of the present invention will be explained in detail.
  • It is considered that cytochrome C transferred from mitochondria to cytoplasm in response to an apoptosis signal is released outside a cell due to destruction of a cell membrane as a result of cell death. The present invention is based on findings that cytochrome C released outside a cell due to cell death can be detected by determining cytochrome C in body fluid such as blood, and that cell death occurring in a living body can be detected by determining cytochrome-C in body fluid. Therefore, any methods for detecting cell death by determining cytochrome C in body fluid fall within the scope of the present invention.
  • The term “cell death” used herein primarily refers to apoptosis. However, it is not easy to identify cell death generally occurring in a living body as apoptosis, and any cell death accompanied by an increase of cytochrome C in body fluid is included in the cell death referred to in the present invention.
  • Further, body fluid refers to blood, plasma, serum, cerebrospinal fluid or the like collected from a living body.
  • As the method for measuring cytochrome C, there can be mentioned an immunochemical method, method utilizing electrophoresis, method utilizing chromatography and so forth. Examples of the methods utilizing electrophoresis include a method wherein polyacrylamide gel electrophoresis is performed to detect cytochrome C as a band, a method wherein capillary electrophoresis is performed to detect cytochrome C as a peak and so forth. Further, as the method utilizing chromatography, a method wherein high performance liquid chromatography is performed to detect cytochrome C as a peak and so forth can be mentioned. In order to increase sensitivity, fluorescence labeling may be used in some cases, but the present invention is not limited to such cases.
  • As the method for measuring cytochrome C, an immunochemical method is preferred in view of sensitivity and simplicity. The term “immunochemical method” used herein refers to a method of determining cytochrome C by using an antibody directed to cytochrome C. As the immunochemical method, there can be mentioned various methods such as a competitive method in which cytochrome C is labeled,. a sandwich method in which an antibody is labeled, a latex bead method in which agglutination of antibody-coated beads is observed and so forth, and they are included in preferred embodiments of the present invention so long as an antibody directed to cytochrome C is used. The antibody may be a monoclonal or polyclonal antibody. As the labeling method, there can also be mentioned various methods such as labeling with a radioactive isotope, labeling with a compound showing electro-chemiluminescence, fluorescence labeling, labeling with an enzyme, labeling with biotin and so forth, but the present invention is not limited to these examples.
  • As an example of the immunochemical method for measuring cytochrome C, a sandwich method will be explained below step by step.
  • 1) An antibody directed to cytochrome C is immobilized on beads or a cup. The beads may be microbeads. In this case, microbeads of magnetic substance are preferred. The immobilization may be achieved by a covalent or non-covalent bond. Usually, nonspecific binding sites on the beads or cup are blocked by using a protein such as bovine serum albumin (BSA) or casein or a surfactant such as Tween 20.
  • 2) A specimen is diluted with a buffer containing a protein such as BSA or casein or a surfactant such as Tween 20, if required, and added to the beads or the cup. Further, a known amount of cytochrome C is similarly diluted and added.
  • 3) The beads or the cup are/is washed with a buffer-containing a surfactant such as Tween 20, if required, and a labeled antibody diluted with a buffer containing a protein such as BSA or casein or a surfactant such as Tween 20, if required, is added thereto.
  • 4) The beads or the cup are/is washed with a buffer containing a surfactant such as Tween 20, if required, and measurement is performed by a method corresponding with the label. For example, radioactivity is measured when it is radioactively labeled, or enzymatic activity is measured when it is labeled with an enzyme. Further, when it is labeled with biotin, labeled avidin is further added and measurement is performed by a method corresponding with the label.
  • 5) A calibration curve is created by using known amounts of cytochrome C, and the amount of cytochrome C contained in the specimen is calculated.
  • With the above steps, cytochrome C in the specimen is determined.
  • When the determined value of cytochrome C is higher than a normal value, it can be considered that cell death is detected.
  • The present invention also relates to a method for measuring cytochrome C, which comprises determining cytochrome C in body fluid by a sandwich method. The sandwich method is an immunochemical method such as ELISA utilizing an antigen sandwiched by an immobilized antibody and a labeled antibody.
  • As the method for measuring cytochrome C by an immunochemical method, a dot blot method is widely used (Souichi A. et al., J. Biological Chem. 273: 19892-4, 1998). However, while this method can measure cytochrome C in a cell homogenate containing a high content of cytochrome C and a low concentration of protein, this is not suitable for determining cytochrome C with high sensitivity in body fluid containing a low content of cytochrome C and a high concentration of protein. The present invention is based on a finding that even such a trace amount of cytochrome C in body fluid as released due to cell death occurring in a living body can be detected by using ELISA based on the sandwich method to determine cytochrome C in the body fluid containing a high concentration of protein with high sensitivity.
  • Further, the present invention also relates to a reagent for measuring cytochrome C, which comprises an antibody directed to cytochrome C as an ingredient and used for determining cytochrome C in body fluid by the sandwich method. This measurement reagent may have the same constitution as that of a reagent (kit) used in a usual sandwich method except that the anti-cytochrome C antibody is used as an antibody. For example, the reagent for measuring cytochrome C by the sandwich method may contain 1) an anti-cytochrome C antibody-coated solid phase such as an anti-cytochrome C antibody-coated cup or anti-cytochrome C antibody-coated beads, 2) a labeled anti-cytochrome C antibody, 3) a cytochrome C standard solution of a known concentration, 4) a diluent and 5) a washing solution. Further, if labeling with an enzyme is used, 6) a chromogenic substrate and 7) a solution for terminating a reaction may be included.
  • The method and the reagent for measuring cytochrome C disclosed by the present invention enable detection of cell death. Therefore, it becomes possible to provide a diagnostic indicator for diagnosis of various diseases accompanied with apoptosis such as differential diagnosis or follow-up of the diseases. Thus., there are provided a method and reagent for measuring cytochrome C for the purpose of detection of cell death or diagnosis of a disease accompanied with apoptosis.
  • As examples of the diseases accompanied with apoptosis, the followings can be mentioned.
  • 1) Diseases in which apoptosis is induced in response to a signal generated by a cell of an immune system responsible for biophylaxis, for example, GVHD and autoimmune diseases (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, Sjogren's syndrome, multiple sclerosis, insulin dependent diabetes mellitus, ulcerative colitis)
  • 2) Diseases in which cell death is induced by viral infection or apoptosis is induced by reaction of a cell of an immune system with a cell infected by a virus, for example, virus associated hemophagocytic syndrome (VAHS) and other viral infections (HCV, HIV, influenza virus)
  • 3) Diseases in which cell death is induced by an abnormal apoptosis signal, for example, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease)
  • 4) Leukemia, for example, acute lymphatic leukemia
  • 5) Diseases in which apoptosis is artificially induced by, for example, radiation exposure or medication (anticancer drug etc.)
  • 6) Systemic inflammatory reaction syndrome (SIRS), diseases in which organ disorder occurs because the immune system is nonspecifically activated in response to invasion to a living body and thus control of cytokine production becomes impossible (HPS, severe pancreatitis)
  • Among the diseases induced by viral infection, those that are severe and likely to leave aftereffects are encephalitis and encephalopathy. In particular, encephalitis and encephalopathy caused by influenza virus account for a large proportion of causes of death by influenza, but it is difficult to differentiate the diseases from heat cramp, and a method of accurate early diagnosis for providing appropriate treatment therefor is required. The measurement method and the measurement reagent of the present invention enable accurate and early diagnosis.
  • By measuring cytochrome C in body fluid, cell death progressing in a living body can be determined, and hence progress of these diseases can be monitored. In particular, in GVHD, hemophagocytic syndrome (HPS), especially virus associated hemophagocytic syndrome (VAHS), acute lymphatic leukemia and influenzal encephalitis or encephalopathy, determination of cytochrome C is useful to understand the conditions of the diseases.
  • As a result of further studies of the inventors of the present invention, it was confirmed that the cytochrome C level in blood well correlated with LDH, which was regarded as an indicator of cell death, in HPS and influenzal encephalopathy, and it was further revealed that increase and decrease of cytochrome C preceded those of LDH.
  • Cytochrome C in body fluid is a favorable indicator of cell death occurring in a living body, and can be a useful indicator to find a pathological condition early and accurately.
    • EXAMPLES
  • The present invention will be explained more specifically with reference to the following examples. However, the scope of the present invention is not limited to these examples. % refers to % by mass unless otherwise indicated.
    • Example 1
  • Measurement of Cytochrome C by ELISA
  • Cytochrome C is measured by the following procedure.
  • 1) Purification of anti-cytochrome C antibody
  • A rabbit is immunized with rat cytochrome C (Sigma) to obtain antiserum directed to cytochrome C. To the antiserum, ammonium sulfate is added at a final concentration of 2 M, and it is stirred at room temperature (20-30° C.) for 5 hours. The stirred solution is centrifuged at 10000 rpm for 30 minutes and the supernatant is discarded. The precipitation is dissolved in 0.1 M phosphate buffer (pH 7.2) and dialyzed against the same buffer. The dialyzed solution is applied to a column of a carrier obtained by binding bovine cytochrome C to CNBr-Sepharose 4B (Pharmacia). The column is washed with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl, and then anti-cytochrome C antibodies are eluted with 0.1 M guanidine hydrochloride. The eluted solution is dialyzed against 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl to obtain purified antibodies (IgG).
  • 2) Preparation of anti-cytochrome C antibody F(ab′)2
  • The purified IgG is dialyzed against 0.1 M acetate buffer (pH 4.2). To the dialyzed IgG solution, pepsin (Sigma) is added in a mass concentration ratio of 20:1 and it is allowed to react at 37° C. for 16 hours. The solution after the reaction is adjusted to pH 7.5 with 1 N NaOH and subjected to gel filtration by using a Sephacryl S-200 (Pharmacia) column equilibrated with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl. A first peak of the fractions obtained from the gel filtration is collected and concentrated to obtain an anti-cytochrome C antibody F(ab′)2 solution.
  • 3) Preparation of horseradish peroxidase (HRP)-labeled anti-cytochrome C antibody F(ab′)2
  • To 1 ml of HRP (Toyobo) solution adjusted to 4 mg/ml, 60 μl of 0.1 M sodium metaperiodate is added, and it is stirred at room temperature (20-30° C.) for 20 minutes, and dialyzed against 0.001 M acetate buffer (pH 4.4). The dialyzed solution is adjusted to pH 9.0-9.5 with 0.2 M sodium carbonate solution. To this solution, 1 ml of the anti-cytochrome C antibody F(ab′)2 solution (4 mg/ml) dialyzed against 0.1 M carbonate buffer (pH 9.5) is added and it is stirred at room temperature (20-30° C.) for 2 hours. Then 50 μl of sodium borohydride solution adjusted to 4 mg/ml is added, and it is stirred at 4° C. for 2 hours and left standing for 16 hours. This solution is dialyzed against a phosphate buffer (pH 7.2) containing 0.15 M NaCl and then subjected to gel filtration by using a Sephacryl S-200 (Pharmacia) column. A first peak of the fractions obtained from the gel filtration is collected and diluted with 0.2 M disodium phosphate buffer (pH 5.4) containing 25% rabbit serum (Nippon Seibutsu Zairyo) to obtain a HRP-labeled anti-cytochrome C antibody F(ab′)2 solution (labeled antibody solution).
  • 4) Preparation of anti-cytochrome C antibody-immobilized cup
  • The purified IgG obtained in 1) is adjusted to an absorbance of 0.1 with 0.01 M Tris-HCl buffer (pH 7.5). 100 μl of this antibody solution is introduced into a polystyrene cup, and allowed to react at 4° C. for 16 hours and the cup is washed three times (for 4 seconds each time) with 0.01 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl and 0.01% Tween 20 by using a washer designed for use in EIA. 200 μl of 0.01 M Tris-HCl buffer (pH 7.5) containing 0.5% bovine albumin is added to the washed cup and allowed to react at 4° C. for 16 hours again to obtain an antibody-immobilized solid phase cup.
  • 5) Preparation of standard antigen
  • Rat cytochrome C (Sigma) is diluted with 0.05 M Tris buffer (pH 7.5) containing 2% BSA, 0.01 M EDTA 2Na, 0.1% NaN3, 0.01% Tween 20 and 0.15 M NaCl to prepare 50-0.05 ng/ml dilutions.
  • 6) Measurement
  • The bovine albumin solution in the anti-cytochrome C antibody-immobilized cup is sucked out and 50 μl of 0.05 M Tris buffer (pH 7.5) containing 2% BSA, 0.01 M EDTA 2Na, 0.1% NaN3, 0.01% Tween 20 and 0.15 M NaCl is introduced into the aforementioned cup. 50 μl each of diluted standard antigen solutions and a specimen is added to the cup and allowed to react at room temperature (20-30° C.) for 1 hour. After the reaction, the cup is washed three times (for 4 seconds each time) with 0.005 M Tris buffer (pH. 7.5) containing 0.01% Tween 20, 0.0015 M NaCl, 0.0015% methyl paraoxybenzoate and 0.005% 2-chloroacetamide by using a washer designed for use in EIA. After the washing, 100 μl of the labeled antibody solution is added and allowed to react at room temperature (20-30° C.) for 1 hour. After the reaction, the cup is washed three times (for 4 seconds each time) with 0.005 M Tris buffer (pH 7.5) containing 0.01% Tween 20, 0.15 M NaCl, 0.0015% methyl paraoxybenzoate and 0.005% 2-chloroacetamide by using a washer designed for use in EIA. After the washing, 100 μl of 0.1 M citrate buffer (pH 4.2) containing 1.5 mg/ml ABTS (2,2-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) is added and allowed to react at room temperature (20-30° C.) for 1 hour, and then 100 μl of 0.013% NaN3 solution is added to terminate the reaction. The absorbance of the color-developed solution is measured at 405 nm by using a spectrophotometer.
  • 7) Characteristics of standard antigen curve
  • Absorbance value of a blank is subtracted from each of absorbance values of the cytochrome C at various concentrations and the specimen. The standard antigen concentration and the absorbance of the standard antigen are plotted on the horizontal axis and the vertical axis, respectively, to draw a standard curve. Based on the standard antigen curve, the amount of cytochrome C contained in the specimen is calculated.
    • Example 2
  • Quantitation of Cytochrome C in Sera of GVHD, HPS and Acute Lymphatic Leukemia Patients
  • Cytochrome C levels in sera of GVHD, HPS and acute lymphatic leukemia patients and normal subjects were measured by using the ELISA system for measuring cytochrome C described in Example 1.
  • As a result, as shown in Table 1, 15 normal subjects were all negative (<0.05 ng/ml), whereas 4 out of 6 GVHD patients were positive (67%), 4 out of 4 HPS patients were positive (100%) and 2 out of 2 acute lymphatic leukemia patients were positive (100%). Further, HPS patients having a high blood cytochrome C concentration tended to show poor course of the disease.
  • Clearly high determined values of cytochrome C were observed in sera of patients where apoptosis was considered to occur.
    TABLE 1
    Determined values of cytochrome C in sera of GVHD,
    HPS and acute lymphatic leukemia patients
    Determined value of cytochrome C
    Disease in serum (ng/ml)
    GVHD 1.1
    <0.05
    0.4
    0.3
    <0.05
    0.3
    HPS (including VAHS) 3.1
    22.0
    38.0
    2.9
    Acute lymphatic leukemia 0.4
    0.4
    Normal subjects* <0.05

    *All the 15 normal subjects had values less than the detection limit (<0.05 ng/ml).
  • Further, changes in values of LDH, AST, ALT, ferritin and cytochrome C in sera of HPS patients are shown in FIG. 1. The cytochrome C value substantially correlated with the LDH and its change preceded that of LDH. Therefore, cytochrome C is considered to be useful as an indicator for sensitively reflecting changes in pathological conditions.
    • Example 3
  • Determination of Cytochrome C in Sera of Influenzal Encephalitis or Encephalopathy Patients
  • The amounts of cytochrome C in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy were measured by using the ELISA system described in Example 1.
  • The results including those of multiple measurements for one patient are shown in FIG. 2. Among the cases accompanied with encephalitis or encephalopathy, all 27 specimens (8 cases) showed high values not lower than 5 ng/ml, and among these, 17 specimens showed high values not lower than 30 ng/ml. Further, patients having a high blood cytochrome C concentration tended to show poor course of the disease.
  • Some patients having repeated heat cramps showed slightly high values, and it was considered that a sufficient care was necessary for these patients. Among patients accompanied with high fever, no patient showed a high determined value of cytochrome C.
  • Further, changes in values of GOT, LDH and cytochrome C in blood of influenzal encephalopathy patients are shown in FIG. 3. Increase and decrease of the cytochrome C level preceded those of LDH, and it was revealed that cytochrome C was useful as a preceding indicator reflecting a pathological condition of influenzal encephalopathy.
    • Example 4
  • Concentrations of Various Cytokines in Sera of Influenzal Encephalitis or Encephalopathy Patients
  • Concentrations of E-selectin, soluble thrombomodulin (sTM), tumor necrosis factor (TNF), Fas, FasL and cytochrome. C in sera of influenza patients accompanied with high fever, heat cramp or encephalitis or encephalopathy were determined. E-selectin was measured by using sE-Selectin ELISA Kit (Version 2, Bender Med Systems). sTM was measured by using TM Test (Teijin Diagnostics). TNF was measured by using Human TNF-α Cytoscreen Immunoassay Kit (Biosource International). Fas was measured by using sFas ELISA Kit, and FasL was measured by using sFas Ligand ELISA Kit (both produced by Medical and Biological Laboratories). Cytochrome C was measured by using the ELISA system described in Example 1.
  • As shown in FIG. 4, for all of the cytokines, number of cases showing high determined values increased for sera of encephalitis or encephalopathy patients. However, cytochrome C most markedly increased in encephalitis or encephalopathy patients. Thus, it was revealed that cytochrome C was the most suitable for differential diagnosis of encephalitis or encephalopathy.
    • INDUSTRIAL APPLICABILITY
  • The present invention provides an immunochemical method suitable for determination of cytochrome C in body fluid. Further, it was revealed that cytochrome C was a favorable indicator of cell death occurring in a living body and a useful indicator to find a pathological condition early and accurately. Therefore, measurement of cytochrome C is useful for diagnosis such as differential diagnosis or follow-up of diseases in which apoptosis is involved in progress of their pathological conditions, in particular, GVHD, HPS, acute lymphatic leukemia and influenzal encephalitis or encephalopathy.

Claims (8)

1-3. (canceled)
4. A reagent for measuring cytochrome C for determination of cytochrome C in body fluid by a sandwich method, which comprises an antibody directed to cytochrome C as an ingredient.
5. The reagent for measuring cytochrome C according to claim 4, which is used for detection of cell death.
6. The reagent for measuring cytochrome C according to claim 4, which is used for diagnosis of graft versus host disease.
7. The reagent for measuring cytochrome C according to claim 4, which is used for diagnosis of hemophagocytic syndrome.
8. The reagent for measuring cytochrome C according to claim 4, which is used for diagnosis of acute lymphatic leukemia.
9. The reagent for measuring cytochrome C according to claim 4, which is used for diagnosis of viral encephalitis or encephalopathy.
10. The reagent for measuring cytochrome C according to claim 9, wherein the viral encephalitis or encephalopathy is influenzal encephalitis or encephalopathy.
US11/402,538 1999-11-08 2006-04-12 Method and reagent for detecting cell death Abandoned US20060183176A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/402,538 US20060183176A1 (en) 1999-11-08 2006-04-12 Method and reagent for detecting cell death

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP11-316475 1999-11-08
JP31647599 1999-11-08
JP2000-274257 2000-09-11
JP2000274257 2000-09-11
PCT/JP2000/007838 WO2001035093A1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent
US10/129,644 US7070924B1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent
US11/402,538 US20060183176A1 (en) 1999-11-08 2006-04-12 Method and reagent for detecting cell death

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2000/007838 Division WO2001035093A1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent
US10/129,644 Division US7070924B1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent

Publications (1)

Publication Number Publication Date
US20060183176A1 true US20060183176A1 (en) 2006-08-17

Family

ID=26568676

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/129,644 Expired - Lifetime US7070924B1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent
US11/402,538 Abandoned US20060183176A1 (en) 1999-11-08 2006-04-12 Method and reagent for detecting cell death

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/129,644 Expired - Lifetime US7070924B1 (en) 1999-11-08 2000-11-08 Method of detecting cell death and detection reagent

Country Status (7)

Country Link
US (2) US7070924B1 (en)
EP (1) EP1229328B1 (en)
JP (1) JP3869722B2 (en)
AT (1) ATE365327T1 (en)
DE (1) DE60035286T2 (en)
ES (1) ES2288877T3 (en)
WO (1) WO2001035093A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263809A1 (en) * 2005-04-05 2006-11-23 The Rgents Of The University Of California Method for sensitive measure of low level apoptosis in cells
US20090075290A1 (en) * 2005-04-15 2009-03-19 Eisai R&D Management Co., Ltd. Immunochemical determination method and determination reagent for cytochrome
US10012648B2 (en) 2014-06-03 2018-07-03 Yale University Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
DE60331310D1 (en) * 2002-06-26 2010-04-01 Univ Louisville Res Found PROCEDURE FOR APOPTOSE DETECTION
JP5176239B2 (en) * 2006-04-06 2013-04-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Non-invasive test method and test kit for non-alcoholic steatohepatitis by quantification of cytochrome c
JP5152766B2 (en) * 2008-03-10 2013-02-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method and test reagent for cancer invasion and metastasis
JP5483141B2 (en) * 2008-04-23 2014-05-07 学校法人日本医科大学 Distinguishing between encephalopathy-derived convulsions and fever-derived thermal convulsions
EP2813848A3 (en) * 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2501800A4 (en) 2009-11-17 2013-05-22 Musc Found For Res Dev HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN
WO2012081701A1 (en) * 2010-12-16 2012-06-21 独立行政法人産業技術総合研究所 Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
PT3446714T (en) 2011-06-02 2021-06-23 Univ Louisville Res Found Inc Anti-nucleolin agent-conjugated nanoparticles
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US20020192712A1 (en) * 2001-05-09 2002-12-19 Fumio Endo Method and reagent for testing for multiple organ failure in sirs by cytochrome C measurement
US20040043435A1 (en) * 2000-07-21 2004-03-04 Marek Los Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms
US20050106561A1 (en) * 2003-11-13 2005-05-19 Yoshiyuki Suzuki Method for predicting the severity of viral hepatitis type B in patients treated with an anti-viral agent, and a kit for diagnosing viral hepatitis type B

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03257367A (en) * 1990-03-08 1991-11-15 Morinaga & Co Ltd Serodiagnosis
FR2659449A1 (en) 1990-03-08 1991-09-13 Morinaga & Co
CA2260766A1 (en) 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US20040043435A1 (en) * 2000-07-21 2004-03-04 Marek Los Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms
US20020192712A1 (en) * 2001-05-09 2002-12-19 Fumio Endo Method and reagent for testing for multiple organ failure in sirs by cytochrome C measurement
US20050106561A1 (en) * 2003-11-13 2005-05-19 Yoshiyuki Suzuki Method for predicting the severity of viral hepatitis type B in patients treated with an anti-viral agent, and a kit for diagnosing viral hepatitis type B

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263809A1 (en) * 2005-04-05 2006-11-23 The Rgents Of The University Of California Method for sensitive measure of low level apoptosis in cells
US20090075290A1 (en) * 2005-04-15 2009-03-19 Eisai R&D Management Co., Ltd. Immunochemical determination method and determination reagent for cytochrome
US7892757B2 (en) * 2005-04-15 2011-02-22 Eisai R&D Management Co., Ltd. Immunochemical determination method and determination reagent for cytochrome c
US10012648B2 (en) 2014-06-03 2018-07-03 Yale University Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy

Also Published As

Publication number Publication date
ATE365327T1 (en) 2007-07-15
JP3869722B2 (en) 2007-01-17
EP1229328B1 (en) 2007-06-20
ES2288877T3 (en) 2008-02-01
US7070924B1 (en) 2006-07-04
DE60035286D1 (en) 2007-08-02
EP1229328A4 (en) 2005-02-23
DE60035286T2 (en) 2008-02-21
WO2001035093A1 (en) 2001-05-17
EP1229328A1 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
US20060183176A1 (en) Method and reagent for detecting cell death
US6916626B1 (en) Detection of Candida
Nakagawa et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
ZA200105058B (en) Kidney disease detection and treatment.
JP2021533384A (en) How to detect biomarkers
JP2021533383A (en) Methods for depletion and enrichment
EP1238284B1 (en) Diagnostic assay for stroke
JPWO2011034182A1 (en) Hepatocellular carcinoma marker
CN110818800B (en) Detection method for indirectly detecting target analyte by constructing bridged complex
EP0710839A2 (en) Method of measuring interferon activity
JP2911602B2 (en) Measurement of enzyme indicators as an aid for diagnosis
US8252548B2 (en) In vitro method for the detection of early-stage liver damage
EP3816628B1 (en) Pancreatic cancer determination marker
EP1256806B1 (en) Method and reagent for testing for multiple organ failure in Systemic Inflammatory Response Syndrome (SIRS) by cytochrome C measurement
JP2008509410A (en) Diagnosis method of liver fibrosis
CN113238060B (en) Kit for predicting or diagnosing myocarditis
US20090311719A1 (en) In vitro method for diagnosing neurodegenerative diseases
JP2023527087A (en) Prediction of sepsis status
JP3896303B2 (en) Test reagent for multiple organ failure in SIRS by cytochrome C measurement
NISHIMURA et al. Enzyme immunoassay for manganese-superoxide dismutase in serum and urine
US20100285501A1 (en) Methods for diagnosing endometriosis
EP2376921A1 (en) Detection of ifi16 in body fluids
Saile et al. Quantification of serum amyloid P by enzyme-linked immunosorbent assay
JP2020016453A (en) Peptide marker for disease associated with septicemia
CN118795128A (en) A diluent component and its application

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ENDO, FUMIO;ADACHI, NAOTO;NUNOI, HIROYUKI;AND OTHERS;REEL/FRAME:017790/0646;SIGNING DATES FROM 20020402 TO 20020410

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EISAI CO., LTD.;REEL/FRAME:019235/0487

Effective date: 20070412

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载